Neuroendocrine Tumors - Pipeline Review, H1 2014


#198002

141pages

Global Markets Direct

$ 2000

In Stock


This report provides comprehensive information on the therapeutic development for Neuroendocrine Tumors, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroendocrine Tumors and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Neuroendocrine Tumors and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Neuroendocrine Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Neuroendocrine Tumors pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Tumors
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Neuroendocrine Tumors Overview 9
Therapeutics Development 10
Pipeline Products for Neuroendocrine Tumors - Overview 10
Pipeline Products for Neuroendocrine Tumors - Comparative Analysis 11
Neuroendocrine Tumors - Therapeutics under Development by Companies 12
Neuroendocrine Tumors - Therapeutics under Investigation by Universities/Institutes 15
Neuroendocrine Tumors - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Neuroendocrine Tumors - Products under Development by Companies 19
Neuroendocrine Tumors - Products under Investigation by Universities/Institutes 20
Neuroendocrine Tumors - Companies Involved in Therapeutics Development 21
Amgen Inc. 21
Tekmira Pharmaceuticals Corp. 22
Merck & Co., Inc. 23
Delcath Systems, Inc. 24
Ipsen S.A. 25
Novartis AG 26
Progenics Pharmaceuticals, Inc. 27
OXiGENE, Inc. 28
Threshold Pharmaceuticals, Inc. 29
Nobelpharma Co., Ltd. 30
Gradalis Inc. 31
Intezyne, Inc 32
Chiasma, Inc. 33
OctreoPharm Sciences GmbH 34
DexTech Medical AB 35
Neuroendocrine Tumors - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 40
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
everolimus - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
lanreotide acetate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
MK-2206 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
panobinostat - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ganitumab - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Edotreotide Labeled Yttrium 90 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
melphalan - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
177Lu-DOTA-TATE - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Somadex - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
pasireotide LAR - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
TH-302 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
TKM-PLK1 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
streptozocin - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
DG-3173 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
SNX-5422 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
octreotide acetate - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
IT-139 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
fosbretabulin tromethamine - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Pbi-shRNA PDX-1 LP - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Peptides For Cancer - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
G-02113 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
OPS-201 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Neuroendocrine Tumors - Recent Pipeline Updates 99
Neuroendocrine Tumors - Dormant Projects 127
Neuroendocrine Tumors - Discontinued Products 128
Neuroendocrine Tumors - Product Development Milestones 129
Featured News & Press Releases 129
Jan 17, 2014: Ipsen announces at ASCO GI that ELECT clinical trial of Somatuline in the control of symptoms in GEP-NET1 patients with carcinoid syndrome met its primary endpoint 129
Jan 14, 2014: Ipsen to set up its own US oncology team for Somatuline Depot Injection in neuroendocrine tumors 130
Oct 21, 2013: OXiGENE Presents Preclinical Data Demonstrating Significant Antitumor Activity of ZYBRESTAT in Pancreatic Neuroendocrine Tumor Model 131
Oct 08, 2013: Tekmira Provides Corporate Update On Oncology Product Candidate TKM-PLK1 132
Sep 28, 2013: Ipsen : results from CLARINET Phase III clinical trial showed the antiproliferative effect of Somatuline in the treatment of non-functioning GEP-NETs 133
Sep 17, 2013: Ipsen announces positive top line results from phase III ELECT study of Somatuline in the control of symptoms in NET patients with a history of carcinoid syndrome 135
Aug 12, 2013: Tekmira commences Phase I/II study of TKM-PLK1 136
Jul 11, 2013: Ipsen announces positive results from phase III CLARINET study of Somatuline Autogel 120mg in gastrointestinal and pancreatic neuroendocrine tumors 136
Aug 06, 2012: Moffitt Cancer Center Researcher And International Colleagues Test New Drug For Patients With Neuroendocrine Tumors 137
Nov 29, 2011: Everolimus Prolongs Progression Free Survival For Patients With Neuroendocrine Tumors, MD Anderson Study Shows 138

Appendix 140
Methodology 140
Coverage 140
Secondary Research 140
Primary Research 140
Expert Panel Validation 140
Contact Us 141
Disclaimer 141

Number of Products under Development for Neuroendocrine Tumors, H1 2014 10
Number of Products under Development for Neuroendocrine Tumors - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Development by Companies, H1 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Development, H1 2014 18
Products under Development by Companies, H1 2014 19
Products under Investigation by Universities/Institutes, H1 2014 20
Neuroendocrine Tumors - Pipeline by Amgen Inc., H1 2014 21
Neuroendocrine Tumors - Pipeline by Tekmira Pharmaceuticals Corp., H1 2014 22
Neuroendocrine Tumors - Pipeline by Merck & Co., Inc., H1 2014 23
Neuroendocrine Tumors - Pipeline by Delcath Systems, Inc., H1 2014 24
Neuroendocrine Tumors - Pipeline by Ipsen S.A., H1 2014 25
Neuroendocrine Tumors - Pipeline by Novartis AG, H1 2014 26
Neuroendocrine Tumors - Pipeline by Progenics Pharmaceuticals, Inc., H1 2014 27
Neuroendocrine Tumors - Pipeline by OXiGENE, Inc., H1 2014 28
Neuroendocrine Tumors - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 29
Neuroendocrine Tumors - Pipeline by Nobelpharma Co., Ltd., H1 2014 30
Neuroendocrine Tumors - Pipeline by Gradalis Inc., H1 2014 31
Neuroendocrine Tumors - Pipeline by Intezyne, Inc, H1 2014 32
Neuroendocrine Tumors - Pipeline by Chiasma, Inc., H1 2014 33
Neuroendocrine Tumors - Pipeline by OctreoPharm Sciences GmbH, H1 2014 34
Neuroendocrine Tumors - Pipeline by DexTech Medical AB, H1 2014 35
Assessment by Monotherapy Products, H1 2014 36
Number of Products by Stage and Target, H1 2014 39
Number of Products by Stage and Mechanism of Action, H1 2014 42
Number of Products by Stage and Route of Administration, H1 2014 44
Number of Products by Stage and Molecule Type, H1 2014 46
Neuroendocrine Tumors Therapeutics - Recent Pipeline Updates, H1 2014 99
Neuroendocrine Tumors - Dormant Projects, H1 2014 127
Neuroendocrine Tumors - Discontinued Products, H1 2014 128
Number of Products under Development for Neuroendocrine Tumors, H1 2014 10
Number of Products under Development for Neuroendocrine Tumors - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Products, H1 2014 18
Assessment by Monotherapy Products, H1 2014 36
Number of Products by Top 10 Target, H1 2014 37
Number of Products by Stage and Top 10 Target, H1 2014 38
Number of Products by Top 10 Mechanism of Action, H1 2014 40
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 41
Number of Products by Top 10 Route of Administration, H1 2014 43
Number of Products by Stage and Top 10 Route of Administration, H1 2014 44
Number of Products by Top 10 Molecule Type, H1 2014 45
Number of Products by Stage and Top 10 Molecule Type, H1 2014 46